Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2019 Filed May 15, 2019 00:21 UTC |
Szyman Catherine M.CVP, Critical Care
|
Tax withholdingCommon Stock | 1,287 | $181.10 | $233,075.70 |
DisclosureSEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,833.5729 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:21 UTC |
Szyman Catherine M.CVP, Critical Care
|
Tax withholdingCommon Stock | 682 | $181.10 | $123,510.20 |
DisclosureSEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,120.5729 Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:21 UTC |
Szyman Catherine M.CVP, Critical Care
|
Exercise / conversionCommon Stock | 2,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,802.5729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:02 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionPerformance Rights · Derivative | 1,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008001 · doc4.xml · derivative · entry 5 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,382 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.underlying_shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:02 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Tax withholdingCommon Stock | 686 | $181.10 | $124,234.60 |
DisclosureSEC source: 0001225208-19-008001 · doc4.xml · nonDerivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,743.1557 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:02 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Tax withholdingCommon Stock | 349 | $181.10 | $63,203.90 |
DisclosureSEC source: 0001225208-19-008001 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,429.1557 Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:02 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionCommon Stock | 1,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008001 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,778.1557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:04 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
Tax withholdingCommon Stock | 85 | $181.10 | $15,393.50 |
DisclosureSEC source: 0001225208-19-007995 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,589.9846 Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:00 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
Tax withholdingCommon Stock | 22 | $181.10 | $3,984.20 |
DisclosureSEC source: 0001225208-19-007994 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,687.8535 Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionPerformance Rights · Derivative | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,784 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.underlying_shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 1,381 | $181.10 | $250,099.10 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,752.3275 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 691 | $181.10 | $125,140.10 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,133.3275 Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:39 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007992 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,824.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,800 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · derivative · entry 10 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,200 Underlying: Common Stock · 32,800 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 8,118 | $179.73 | $1,459,077.36 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,800.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F7 · price: This transaction was executed in multiple trades at prices ranging from $179.1600 to $180.1300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 7,780 | $180.52 | $1,404,476.72 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,918.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F6 · price: This transaction was executed in multiple trades at prices ranging from $180.1700 to $181.0700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 6,152 | $176.77 | $1,087,460.74 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,698.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F5 · price: This transaction was executed in multiple trades at prices ranging from $176.1500 to $177.1400. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 5,338 | $178.75 | $954,184.58 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,850.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $178.1600 to $179.1500. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 4,175 | $177.53 | $741,198.61 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,188.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $177.1500 to $177.9900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 1,237 | $181.41 | $224,405.41 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,363.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $181.1700 to $181.5900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2019 Filed May 13, 2019 22:57 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 32,800 | $35.79 | $1,173,748.00 |
DisclosureSEC source: 0001225208-19-007864 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,600.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC |
STONE HEISZ LESLIEDirector
|
GrantCommon Stock | 311 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007858 · doc4.xml · nonDerivative · entry 2 STONE HEISZ LESLIE · CIK 0001235408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,323 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC |
STONE HEISZ LESLIEDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007858 · doc4.xml · nonDerivative · entry 1 STONE HEISZ LESLIE · CIK 0001235408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,012 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:39 UTC |
VON SCHACK WESLEY WDirector
|
GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007863 · doc4.xml · nonDerivative · entry 2 VON SCHACK WESLEY W · CIK 0001025355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,737 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:39 UTC |
VON SCHACK WESLEY WDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007863 · doc4.xml · nonDerivative · entry 1 VON SCHACK WESLEY W · CIK 0001025355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:38 UTC |
VALERIANI NICHOLAS JDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007862 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,995 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:37 UTC |
Marsh Martha H.Director
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007861 · doc4.xml · nonDerivative · entry 1 Marsh Martha H. · CIK 0001500281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,953 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC |
LINK WILLIAM J PHDDirector
|
GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007860 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,467 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC |
LINK WILLIAM J PHDDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007860 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,053 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC |
LORANGER STEVEN RDirector
|
GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007859 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC |
LORANGER STEVEN RDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007859 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,541 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:34 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007857 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,737 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:34 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007857 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 08, 2019 Filed May 8, 2019 22:10 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001223203-19-000023 · primary_doc.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 08, 2019 Filed May 8, 2019 22:10 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
SaleCommon Stock | 300 | $178.54 | $53,562.00 |
DisclosureSEC source: 0001223203-19-000023 · primary_doc.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,115.3275 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 08, 2019 Filed May 8, 2019 22:10 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 300 | $42.73 | $12,817.50 |
DisclosureSEC source: 0001223203-19-000023 · primary_doc.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,415.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:48 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GrantPerformance Rights · Derivative | 10,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000038 · primary_doc.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,825 Underlying: Common Stock · 10,825 shares Expires 2026-05-07 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:48 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 85,600 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000038 · primary_doc.xml · derivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,600 Underlying: Common Stock · 85,600 shares Expires 2026-05-07 F3 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:48 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GrantCommon Stock | 8,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000038 · primary_doc.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,800.82 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:04 UTC |
Wood Larry LCVP, TAVR
|
GrantPerformance Rights · Derivative | 2,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000036 · primary_doc.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,525 Underlying: Common Stock · 2,525 shares Expires 2026-05-07 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:04 UTC |
Wood Larry LCVP, TAVR
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 17,900 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000036 · primary_doc.xml · derivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,900 Underlying: Common Stock · 17,900 shares Expires 2026-05-07 F3 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:04 UTC |
Wood Larry LCVP, TAVR
|
GrantCommon Stock | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000036 · primary_doc.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,803.9386 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:27 UTC |
BOBO DONALD E JRCVP, Strategy/Corp Development
|
GrantPerformance Rights · Derivative | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000037 · primary_doc.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires 2026-05-07 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:27 UTC |
BOBO DONALD E JRCVP, Strategy/Corp Development
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 18,900 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000037 · primary_doc.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2026-05-07 F3 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:27 UTC |
BOBO DONALD E JRCVP, Strategy/Corp Development
|
GrantCommon Stock | 1,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000037 · primary_doc.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,040.3275 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:11 UTC |
WANG HUIMINCVP, Japan, Asia & Pacific
|
GrantPerformance Rights · Derivative | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000035 · primary_doc.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan, Asia & Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325 Underlying: Common Stock · 1,325 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:11 UTC |
WANG HUIMINCVP, Japan, Asia & Pacific
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 10,600 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000035 · primary_doc.xml · derivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan, Asia & Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:11 UTC |
WANG HUIMINCVP, Japan, Asia & Pacific
|
GrantCommon Stock | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000035 · primary_doc.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan, Asia & Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,396.1557 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:00 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
GrantPerformance Rights · Derivative | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000031 · primary_doc.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 1,625 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:00 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 12,800 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000031 · primary_doc.xml · derivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.